Recent Analysts’ Ratings Updates for Neumora Therapeutics (NMRA)

A number of firms have modified their ratings and price targets on shares of Neumora Therapeutics (NASDAQ: NMRA) recently:

• 7/28/2026 – Neumora Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 7/25/2026 – Neumora Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 7/17/2026 – Neumora Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/13/2026 – Neumora Therapeutics had its price target lowered by Royal Bank Of Canada from $7.00 to $5.00. They now have an “outperform” rating on the stock.
• 6/18/2026 – Neumora Therapeutics had its price target lowered by Mizuho from $6.00 to $4.00. They now have an “outperform” rating on the stock.
• 6/16/2026 – Neumora Therapeutics had its price target lowered by HC Wainwright from $18.00 to $7.00. They now have a “buy” rating on the stock.
• 6/16/2026 – Neumora Therapeutics had its price target lowered by Needham & Company LLC from $8.00 to $5.00. They now have a “buy” rating on the stock.

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.